Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SOKOL...Excellent work. Thank you.
Well LONGS and any potential patient, are we READY FOR BIG WEEK???
plexrec
From Richard @ Yahoo bd..I agree..
powerwalker
Hoskuld
Hoskuld
Grade 3 (severe)
5 ANAVEX2-73-002 (N=32; 57 weeks)
6 ANAVEX2-73-003 (N=24; interim 148 weeks)
MKc12five
Request this pinned to the top. Thanks falconer66a
"Anti-aging may be the biggest Anavex story.
It is very, very likely that Anavex will treat glaucoma...and probably dozens of other diseases of aging.
falconer
Today, no one is actually questioning blarcamesine's MOA anymore. Competent research biochemists and cellular physiologists in labs and universities across the land have scrutinized the available information and they remain silent. Like the rest of us, they've discovered the abundant evidence showing positively that blarcamesine as a sigma-1 receptor ligand really does induce good therapeutic downstream processes.
After devoting an entire career to perfect monoclonal antibodies to digest beta-amyloids it must not be pleasant to be confronted with Anavex science. It obviates everything in the past and the future. End of career. Go learn and do something else.
Or, decide not to read or learn anything about Anavex science and pretend it doesn't exist? Sure.
DFRAI...WOW...
Subgrouping and structural brain connectivity of Parkinson’s disease –
past studies and future directions
Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder associated with several motor and non-motor dysfunctions. The wide variety of clinical features often leads to divergent symptom progressions. Most PD studies have attempted subgrouping based on clinical features to help understand the disease etiology and thereby contribute toward specific treatment. However, clinical symptoms have proven to be overlapping, arbitrary, and non-reliable in several cases, often biasing the deciphered subgroups. Moreover, the prodromal phase complicates diagnosis and subgrouping as it is characterized by limited clinical symptom expression. Hence, recent studies have used data-driven machine learning
and deep learning methods to data-mine the heterogeneity and obtain subgroups. Structural Magnetic Resonance Imaging (sMRI) is a non-invasive approach for visualization and analysis of anatomical tissue properties of brain. It has enabled the detection of brain abnormalities and is a potential modality for subgrouping
https://reader.elsevier.com/reader/sd/pii/S2772528622000620?token=8723A340B99999B7CBA0CE35F83F3D9499F98C5265B70CA178A378103FFBA97B0918417010F079752440B104C005CBD7&originRegion=us-east-1&originCreation=20221123010146
xodcode[quote]I seriously think the market does not yet understand the AVXL science.[/quote] Totally agree w/this comment. The fact that Dr.M. and the AXL team have multiple examples of unique trial results/models for new spin-off molecules reminds me a lot of the semiconductor device startup-companies of the 70's. Unconstrained breakthrough technical potential, which a lot of people never did figure out until it was to late for them
xodcode
Everything to date is positively converging on A2-73 excellent results!
Watch and learn!
WGT!
WGT!
11.38-0.05 (-0.45%)
As of 03:19PM EST. Market open.
Been a long day but is ending OK.
Well Done,
powerwalker
TGD has stated @ Guggenheim that the higher dose of 50mg showed cognitive improvement in PDD participants and then said that dose was used in the AD P2b/3 trial. Meanwhile, he noted 30 mg stopped the decline in PDD; same dose used in AD trial, too.
This message appears on my Ihub screen as of about 1 hr ago?
Anyone else? Comments ?
"Some market data feeds are down due to a datacenter power outage."
IMO, we are seeing our typical WS -BIO Roller Coaster routine. Drain out SP at the start, edged on by anxiety as falloff continues...at some planned low point...those who sold off JUMP on and pump on the way up. The better the TLR the higher she goes...then they BAIL OUT...repeat as situation presents...disgusted w/this BS.
The timing of TLR pub is a big variable...we'll see. Serious shareholders like myself despise this BS. It appears we have no control and AVXL long term plans/timing are as yet undetermined .
Would most like to see AVXL staff help us get rid of MM and street people.
U.S. stock markets are closed on the following days in 2022: New Year's Day, Martin Luther King, Jr. Day, President's Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving Day, and Christmas. Markets also close early on Black Friday and Christmas Eve.
What Days Are the U.S. Stock Exchanges Closed in 2022?https://www.investopedia.com › Markets › US Markets
Yeah.. the market was liking for
confirmation of bull move
and when longs backed off..
Would think we would see up by end of day..
Best to all AVXL owners down the final stretch. We are in the club house turn now heading into the first finish line , in good shape to take the roses. Most of us would not be here if the data/performance was seriously flawed. We have done our homework. Of Course, the liars and thieves are out there but the time for scientific lies is behind us , it's factual results time or STXU. (data-surprises will not be tolerated at this point and we all know that)
Many thanks and best wishes to Dr. M./Dr. Mac. and the AVXL teams who got us here. IMO, THIS TIME PERIOD MARKS THE END OF THE BEGINNING
THIS is NOT THE TIME FOR SURPRISES.
All the best.
November 20 2022 - 08:55PM
TipRanks
Print
Share On Facebook
Berenberg Bank analyst Caroline Palomeque initiated coverage with a Buy rating on Anavex Life Sciences (AVXL - Research Report) on November 18 and set a price target of $40.00. The company's shares closed last Friday at $12.68.According to TipRanks, Palomeque is an analyst with an average return of -14.6% and a 33.03% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Denali Therapeutics, and RegenXBio.Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $39.25, representing a 209.54% upside. In a report released on November 14, H.C.
https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-initiated-with-a-buy-at-berenberg-bank?utm_source=advfn.com&utm_medium=referral
McM
Quick read..Sounds like more of a chemical than drug..
Used to make other drugs more BioAvailable..
My guess is that AVXL has some carefully calibrated factual leaks which can/may be released at precise intervals over next few weeks, this will leave the criminals to wallow in their own tangled shat.
We know/see what is going on. The criminals are executing their plan. Many innocent CNS disease people suffer while WS criminals go on doing what they do for $$.
Kentucky
That is the plan. They want as few on board as possible.
If Cramer ever saw AVXL potential for the potential good it will do...(NOT THE DEALS HE CAN MAKE) ...and he was able to articulate that....THEN he might add some value. IMO. ...OTHERWISE...ONE WONDERS?????
tredenwater2
why ever would Dr Missling agree to this?
So I think we can all agree that Missling has the TLR by now. So why is he not releasing the TLR? Does any one have any realistic opinions? I think we can rule out a trial failure. The only obvious situation to me is that the results are mixed and need some explaining which he will have time to do at CTAD
Thx La Flaca.
Yup, I have been here since pre-spilt also. Seen em' come , and seen em' go. AVXL team have done a lot of great work.
I remain a big believer of the science along w/many other here . I do support the MOA story and have for years...new $15 owners are more than welcome . Considering how much progress has been made (IMO) our SP should be responding better right now to the great work/results/and promise of the overall AVXL team.
IMO, we should be moving SP in correlation to results and astounding science-medical promise on the table.
Why is OUR SP not showing signs of change/life? Shouldn't we be flying??? Even the despised FUD AXXholes are quiet?
OH WELL, they did not accept-react w/support to the Antibiotic news either.
SOMEONE DECLARE AN AHHHHAAA MOMENT...TIA.
lomgtimer
we may get a early christmas gift and fireworks this year loongs.
If you listen carefully you will hear a giant BP FLUSHING SOUND COMING FROM WS...BAH_BYE BOYS...IMO.
As Anavex has seen DDIT3 levels restored to normalcy, this is an extremely exciting revelation. Combining electron support chain and UPR gene restoration, Anavex has proven with in-patient data how Blarcamesine reduces neuroinflammation, preserves calcium and nutrient funneling, and prevents cascading cell death which simultaneously enables healthy (adaptive) protein clearing."
MAYO...WOW...top shelf stuff...congrats...WELL DONE.
We believe this data will be immeasurably important for Blarcamesine's regulatory approval, as it hones in on upstream therapeutics provided by the drug. The level of analytic rigor conducted by Anavex, Ariana, and third-party scientific benefactors currently supersedes that of even the highest tier biopharmaceutical companies. SOTC Analytics assesses this level of data scrutinization will almost certainly propel Anavex to approval, pending a successful readout of Anavex's 2b/3 Alzheimer's trial.
WOW...took the words right out of my mouth...would add BRILLIANT collection of medical/clinical facts.
Cannot wait for the next steps. Nothing even close to Dr. M and team.
The FDA and other WW regulatory bodies will want/need to adjust their normal process time according to expected findings and the urgent need to move forward.
tredenwater2
[.I really don't understand how the man sleeps at night knowing what he knows, remarkable.]
Encouraged by trial results after so many years of planning/executing/assessing IMO, he is near the close of a long journey in leading edge science. I am also now even more excited about the AVXL-FDA peer reviewed pub(s) . This is just a peek, there are going to be a lot of light sleepers once the rest of the AVXL CNS patient recovery stories begin to flow.
IMO, we are getting an opening peek at the most consequential medical/clinical story since penicillin. I do also expect a fast track assessment process. IMO, a lot of very happy -hopeful people will want to see family and friends recover their lives. I hope to be one of them.
ckent
The most confident and excited I've ever heard Missling! I wish it were on video so we could all see the grin on his face, like a child about to open a Christmas present knowing exactly what he asked for was inside, with only a box, some wrapping paper, and a bow standing between them. He really drove home that past success on PDD foreshadows success in the upcoming Alzheimer's TLD, and presented like a man with three home runs in his back pocket (Alzheimer's, PDD and Retts) with many more to come.
“Assisting the body in re-establishing homeostasis could very well be a key therapeutic step to solving several life-altering CNS conditions.”
Christopher U. Missling PhD, MS, MBA
President and CEO....
Maybe dr.M. is suggesting that time spent chasing Amyloid Plaque would be better invested if BP just turned around and looked upstream? (for the links to causes) HUH?....just start looking for the cause and stop picking through the entrails of symptoms.
IMO, as long as our potential competitors keep doing what they have been doing, then we will have fewer worries.
jager997...is ANYONE (including shorters) stupid enough to jump in front of a speeding locomotive right now??? ...(NOW, THAT'S THE DEFINING WORK IN STUPID).
1950jtom
I have been debating my exit strategy should Avenex turn out to have a novel MOA that successfully treats a variety of conditions (they are looking at seven different ailments at the moment). Treatment for two of those conditions would be blockbusters in the marketplace.
Some of us have short investment timelines, and our goal isn't to die rich leaving someone else a fortune. I could see us pulling out around the $100 mark. Others with much longer investment horizons might hold out for years, letting the stock run up into the hundreds (the potential is there IF....).
In short, there is no one-size-fits-all strategy. I just hope we all make a really nice profit and the only question is, how much.